'
Supriya
Lifescience hosted a conference call on May 28, 2025. During the call, the
company was represented by Dr. Satish Wagh, Executive Chairman & WTD; Dr.
Saloni Wagh, Managing Director; and Mr. Krishna Raghunathan, Chief Financial
Officer.
Key takeaways of the call
The company
reported strong revenue growth in FY25 supported by modest volume growth and
export business.
Focus on niche
and high value products has led to significant improvement in EBITDA margin.
Management
reaffirmed its revenue growth guidance of approximately 20%, targeting Rs 1,000
crore in revenue by FY27, along with an EBITDA margin between 33% and 35%.
With
the launch of new products, margins are expected to compress slightly in FY26;
however, the company anticipates healthy growth in the absolute levels of both
EBITDA and PAT.
In
Q4 FY25, Asia contribu...
Pleaselogin & subscribe to view the full report.
More Reports
|
|